BIRC5 vaccines for cancer immunotherapy have successfully passed proof-of-concept and have already been applied in clinical trials to treat malignant glioblastoma, ovarian cancer, breast cancer, colon cancer, lung cancer, and the like [53,54,55,56]. This evidence concerns the gene BIRC5 and ovarian carcinoma.